Echo Therapeutics has initiated a clinical study of its Symphony tCGM System in patients with type 1 and type 2 diabetes. The company expects to complete and announce the results of the study in the fourth quarter, and plans to subsequently begin a separate study in critical care patients.

Echo plans to enroll in the clinical study up to twenty-five (25) patients with either type 1 or type 2 diabetes and to compare data obtained from its Symphony tCGM System with both the YSI 2300 STAT Plus Glucose Analyzer and a commercially available professional-use glucometer.  The study is expected to collect more than 2400 data pairs to be used in the analyses by taking frequent reference glucose measurements for 24 hours. The study data will be blinded to study subjects and study personnel. A comparison of the data relative to the reference blood glucose values will be used to assess the accuracy of Symphony.